Jun 27, 2019
Ira Pastor, ideaXme longevity and aging Ambassador and founder of Bioquark interviews Dr. Shai Shen-Orr, Founder and Chief Scientist of CytoReason and Associate Professor Technion, Israel Institute of Technology.
Ira Pastor comments:
The year is now 2019 and we have surpassed $7 trillion in total annual healthcare expenditures around the globe. As part of that $7 trillion, we’re now spending close to a $1 trillion a year on pharmaceutical products.
As we’ve been watching the traditional pharma product basket change over the last century, from small organic molecules drugs and vaccines to larger macromolecule biologics (proteins and antibodies), and now into an era of gene and cell therapies, as well as other therapeutic modalities, the tools that allow these discoveries and development of these novel interventions have been changing as well.
A set of tools that we have been hearing quite a bit about in recent years is the triad of artificial intelligence, machine learning, and deep learning, and their respective applications in the drug discovery and development processes.
Artificial intelligence in general is defined as a computer system able to perform tasks that normally require human intelligence, examples including, but not limited to, visual perception, speech recognition, translation and decision-making.
Machine learning is a branch of artificial intelligence that involves methods of data analysis that automate analytical model building and is based on the idea that systems can learn from data, identify patterns, and make decisions with minimal human intervention.
Deep learning is a machine learning technique that teaches computers to do what comes naturally to humans: learning by example.
In the example of the driverless car business, deep learning technology can enable cars to recognize a stop sign, or to distinguish a pedestrian from a lamppost.
In a recent show we did with a colleague in big pharma, as of last week his internal competitive intelligence group counted 153 companies currently attempting to apply this set of AI tools in some fashion to the drug discovery process, so needless to say, it is an area that is really heating up.
So, for today’s guest, I could think of no one better to come and talk with us for a while about this exciting, evolving set of R&D tools in the bio-pharma space, and some of their real world translational possibilities, than Professor Shai Shen-Orr, Associate Professor at Technion - Israel Institute of Technology and founder and Chief Scientist of CytoReason.
Professor Shen-Orr has a PhD from Harvard University in Molecular Cell Biology and Bioinformatics and runs the The Shen-Orr Lab for Systems Immunology and Precision Medicine at Technion, where their core focus is on understanding how immunity is orchestrated in humans and how to apply this knowledge towards advancing genomic medicine.
The lab combines experimental and computational approaches to cover three main themes: identifying biomarkers of immune health, translating this understanding to model organisms and humans, and to understand the system-level properties of immunity and harness these insights to understand complex systems in general.
Dr. Shen-Orr founded CytoReason in 2016, based on more than a decade of his research, not just from Technion but also his previous work at Stanford.
With the understanding we now have of the human immune system being at the epicenter of so many different pathologies in 2019, both direct (autoimmune disease / allergies), to its use as a biotherapeutic tool (immunotherapies) to all of the secondary aspects of inflammation where we see connections to pathologies such as cardiovascular disease, cancer, neuro-inflammation in the case of Alzheimer’s, as well as aging in general and the topic of the “inflamm-aging” processes, I thought he’d make for a great guest with whom to discuss this fascinating topic.
Today, we will hear how Professor Shen-Orr’s became interested in science, bioinformatics and molecular biology, and ultimately how he finds himself in 2019 at the epicenter of the very "hot" area of the biopharma drug discovery and development process. We will also hear a general overview of AI, deep learning, in the healthcare and biopharma space,. Furthermore, we share a discussion about CytoReason and its platform, CytoReason’s collaborations with big pharma, as well as information relating to the bio start-up ecosystem in Israel.
ideaXme is a global podcast, ambassador and mentor programme. Mission: Move the human story forward!™ ideaXme Ltd.